Truist Securities Reiterates Buy Rating on Exelixis (EXEL)

Truist Securities analyst Asthika Goonewardene reiterated a Buy rating and $49.00 price target on Exelixis (NASDAQ: EXEL).

The analyst commented: "With ESMO 2025 almost upon us, we are refining our expectations for the STELLAR-303 data (see prior note: ESMO Expectations: STELLAR-303...). #1 We reiterate expectations for the prescribing community to want numerically comparable data to a newer standard in colorectal cancer (Lonsurf + Bev) to change practice in the broader patient population. #2 Investor expectations are split; investors focused on Zanza's success in a subgroup of colorectal cancer (non-liver met, or NLM) may only require "good enough" data in this allcomer update at ESMO, to keep the NLM thesis going until an official NLM read-out"

For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.

Shares of Exelixis closed at $38.44 yesterday.

You May Also Be Interested In

• Stifel Starts Arrowhead Pharma (ARWR) at Buy
• Western Midstream Partners (WES) PT Raised to $51 at Mizuho
• U.S. began launching strikes against Iran today - Bloomberg